Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
NCT03891615 · Massachusetts General Hospital · PHASE1 · terminated · last registry update 2026-09-21 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual.” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP2 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-25Results posted on the registry: CellCentric Ltd., CCS1477 + Abiraterone acetate (NCT03568656)
- 2026-09-22Also stopped (terminated): National Cancer Institute (NCI), Olaparib + Durvalumab (NCT04538378)
- 2026-08-13Also stopped (terminated): National Cancer Institute (NCI), EP0057 + olaparib (NCT02769962)
- 2026-05-01Results posted on the registry: GlaxoSmithKline, Niraparib + Pembrolizumab (NCT04475939)
- 2026-04-09Also stopped (terminated): M.D. Anderson Cancer Center, Adagrasib + Olaparib (NCT06130254)
- 2026-04-06Also stopped (terminated): Gustave Roussy, Cancer Campus, Grand Paris, Olaparib + Placebo (NCT02679963)
- 2026-02-12Results posted on the registry: University of Michigan Rogel Cancer Center, Pembrolizumab + Pemetrexed (NCT03559049)
- 2026-02-12Also stopped (terminated): University of Michigan Rogel Cancer Center, Pembrolizumab + Pemetrexed (NCT03559049)
- 2025-10-27Results posted on the registry: AstraZeneca, Durvalumab + Danvatirsen (NCT03334617)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision